港股市场上，海西新药 (02637) 股价表现强劲，上涨超过3%。根据最新交易数据，截至发稿时，该股报195.5港元，涨幅达到2.89%，成交金额为618.26万港元。
从消息面看，公司发布公告透露，其自主研发的创新药项目HXP056的候选药物HX9428，已于2026年8月31日向中国国家药品监督管理局药品审评中心正式提交了针对新适应症糖尿病性黄斑水肿的IIa期临床试验申请。
糖尿病性黄斑水肿是HX9428推进的第二个适应症，这一进展标志着该口服眼底创新药物研发历程中的又一重要里程碑。公司方面表示，将持续全力推动HX9428在中美两地的多项临床研究进程。
值得注意的是，HX9428此前已获得美国食品药品监督管理局授予的快速通道资格，并正同步在中美两地开展其首个适应症——新生血管性年龄相关性黄斑变性（即湿性年龄相关性黄斑变性）的II期临床研究工作。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.